Study of ONO-1101 in Patients Scheduled for Coronary Angiography

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in patients scheduled for coronary angiography, in a double-blind, randomized, placebo-controlled, parallel group, multi-center study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ono Pharmaceutical Co. Ltd
• Treatments: Landiolol

Criteria

Inclusion Criteria:

• 20 years of age or older

• Heart rate less than 90 beats/min and more than 70 beats/min at entering the CT room

Exclusion Criteria:

• Previous allergic reactions to contrast agent

• Renal failure

• Asthma

• Concomitant beta-receptor blocking agent